S100A9 is an important alarmin in vivo,which plays a role in regulating inflammation and tumorigenesis.Recently,many studies have also explored the biological function and related mechanism of S100A9 in renal diseases,including acute kidney injury,chronic kidney disease,renal stone,renal transplantation,renal tumor,renal cyst,and urinary infection.They pointed out the potential role of S100A9 as a new diagnostic and therapeutic biomarker for renal diseases.In the current study,we conduct a review of these findings and summarize possible future study directions,which aims to help people understand the impact of S100A9 on renal diseases.

Skin flaps are frequently employed in plastic and reconstructive surgery to address tissue defects.However,their low survival rates remain a challenge,attributed to vascular crisis and necrosis.Despite numerous studies investigating drugs to alleviate flap necrosis,a comprehensive analysis of the research trend in this critical area is lacking.To gain a deeper understanding of the current status,research focal points,and future trends in drugs aimed at enhancing flap survival,a thorough retrospective analysis is imperative.This study aims to employ bibliometric methods to scrutinize the evolution,mechanisms,and forthcoming trends of drugs targeting flap survival improvement.Using VOSviewer software,we quantitatively and visually depict 1)annual temporal trends in the number of documents and citations;2)national/regional publications and their collaborations;3)institutional and authors'contribution;4)journal contribution and relevance;and 5)analysis of research hotspots and directions derived from keywords.Ultimately,we discussed the prospects and challenges of future advances and clinical trans-lation of drugs designed to enhance skin flap survival.In conclusion,the field of pharmacology dedicated to improving skin flap survival is expanding,and this study aims to offer a fresh perspective to promote the advancement and clinical application of such drugs.